candidiasis

Fosravuconazole L-lysine ethanolate (BMS-379224 L-lysine ethanolate) is a broad-spectrum antifungal agent approved in Japan for treating onychomycosis, a fungal nail infection. It is a prodrug converted into ravuconazole.

Albaconazole (W-0027) is a small molecule fungal cytochrome P450 family member 51 (fungal CYP51A1) inhibitor. It is used in the treatment of fungal infections, skin and musculoskeletal disorders, and can be used in the study of vulvovaginal candidiasis, Chagas disease and genitourinary disorders.

Amorolfine hydrochloride (Amorolfine HCl) is an antifungal reagent. It exerts the antifungal activity by selectively interrupting two steps in the pathway of ergosterol synthesis and eventually disrupting the function and structure of fungal cell membrane. Amorolfine hydrochloride , a morpholine antifungal drug, can inhibit D14 reductase and D7-D8 isomerase. These enzymes can deplete ergosterol and cause ignosterol to accumulate in the fungal cytoplasmic cell membranes.

Multifungin (Bromochlorosalicylanilide) is an antifungal agent used in studies of oral candidiasis, reducing fungal populations in stored corn and preventing zearalenone formation and accumulation.

Fluconazole (UK-49858) is a triazole antifungal agent used to treat oropharyngeal candidiasis and cryptococcal meningitis in AIDS.

Nystatin (Fungicidin) is a topical and oral antifungal agent with activity against many species of yeast and candida albicans, which is used largely to treat skin and oropharyngeal candidiasis.

P-113 acetate is an antimicrobial peptide (AMP) derived from the human salivary protein histatin 5, shows good safety and efficacy profiles in gingivitis and human immunodeficiency virus (HIV) patients with oral candidiasis.

Chlordantoin is an antifungal agent with the potential for vaginal candidiasis treatment.

CYP51 Hsp90-IN-1 (Compound MM4) is a dual inhibitor of CYP51 and Hsp90. This compound exhibits antifungal activity against Candida albicans and effectively suppresses key fungal virulence factors. CYP51 Hsp90-IN-1 shows potential for research in treating invasive candidiasis.

Candicidin is an antifungal heptaene macrolides from Streptomyces griseus or Actinomyces levoris used topically in candidiasis. The antibiotic is composed of candicidins A, B, C, and D, of which D is the major component.

CYP51 HDAC-IN-1 is an orally active, potent, dual CYP51 HDAC inhibitor that inhibits important virulence factors and down-regulates the expression of associated drug resistance genes.CYP51 HDAC-IN-1 has shown effective therapeutic effects in both Candidiasis tropicalis and Cryptococcal meningitis.

Antibacterial Agent 84, an antifungal compound, effectively inhibits candidiasis through a CNB1-dependent mechanism and reduces the viability of the C. albicans biofilm [1].

Antifungal agent 73 (compound A32) effectively combats azole-resistant candidiasis by disrupting the fungal cell wall and membrane, demonstrating potent in vivo activity against pathogenic fungi, including fluconazole-resistant strains [1].

Efungumab, a monoclonal antibody exhibiting antifungal properties, specifically targets HSP 90 to inhibit a conformational alteration crucial for fungal survival. It is employed in investigations concerning invasive candidiasis (IC) [1].

Fluconazole-d4 is a deuterated compound of Fluconazole. Fluconazole has a CAS number of 86386-73-4. Triazole antifungal agent that is used to treat oropharyngeal candidiasis and cryptococcal meningitis in AIDS.

Micafungin metabolite M1 is an active metabolite of Micafungin, generated through metabolism by arylsulfatase, and exhibits antifungal activity. It can be utilized in research on deep fungal infections caused by Candida species (Candidiasis) and Aspergillus species (Aspergillosis).